Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid syndrome.

Angelo Ravelli1, Alberto Martini

  • 1Pediatria II, Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Largo G. Gaslini, 5, 16147, Genoa, Italy. angeloravelli@ospedale-gaslini.ge.it

Pediatric Clinics of North America
|April 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.

Annals of the rheumatic diseases·2024
Same author

One-year outcomes of same-day-discharge robot-assisted radical prostatectomy.

BJU international·2024
Same author

Robotic-assisted radical cystectomy with cutaneous ureterostomies: a contemporary multicenter analysis.

World journal of urology·2024
Same author

How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.

BJU international·2024
Same author

Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].

European urology·2024
Same author

Complications of immuno-oncology care: what urologist should know.

BJU international·2024
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Antiphospholipid syndrome (APS) causes blood clots and pregnancy loss. In children, APS is a leading cause of vascular thrombosis, requiring specialized research for effective management.

Area of Science:

  • Autoimmune diseases
  • Pediatric rheumatology
  • Vascular thrombosis

Background:

  • Antiphospholipid syndrome (APS) is an autoimmune disorder.
  • Characterized by thrombosis and/or pregnancy morbidity with antiphospholipid antibodies (aPL).
  • APS is the primary cause of vascular thrombosis in pediatric patients.

Observation:

  • The clinical presentation and management of pediatric APS may differ from adults.
  • aPL-related thrombosis is rare in children.
  • Limited large-scale studies exist on the natural history and optimal treatment of childhood APS.

Findings:

  • Pediatric APS requires distinct diagnostic and therapeutic strategies compared to adult APS.
  • Further multicenter, controlled studies are essential to elucidate the natural history of APS in children.

Related Experiment Videos

  • Defining optimal management protocols for pediatric APS necessitates comprehensive research.

    • Implications:

    • Establishing evidence-based guidelines for pediatric APS diagnosis and treatment.
    • Improving long-term outcomes for children with APS.
    • Highlighting the need for collaborative research efforts in pediatric rheumatology and thrombosis.